TYRA at a glance
Tyra Biosciences, Inc. (TYRA, SEC CIK 1863127) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 15, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Tyra Biosciences, Inc. (TYRA) shares worth $708.4 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by RA CAPITAL MANAGEMENT, L.P. on September 15, 2026 of 9,078,529 shares at $22.03 per share.
- In the last 90 days, TYRA insiders reported 1 open-market purchase ($20K) and 0 open-market sales ($0) on Form 4, a net purchase of $20K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$20K
- 13F holders
- 26 funds
- $708.4M · +0 vs prior quarter
- Latest 8-K
- Sep 15, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- Equity issuance risk: ATM capacity expanded from fully utilized $150.0 million to up to $250.0 million on August 4, 2026
- Dilution risk: Additional common-stock sales enabled under the amended Sales Agreement
- Insider-trading compliance: Five officers and directors adopted trading arrangements during the quarter
- Executive equity-sale risk: Chief Medical Officer plan authorizes sales of up to 74,000 shares through February 26, 2027
AI summary of the TYRA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- $400.0M gross proceeds from 9,079,000 shares and 9,078,529 pre-funded warrants
- Underwritten offering priced at $22.03 per share, with underwriters purchasing at $20.7082
Item EX-99.1: Item EX-99.1
- $400.0M gross equity offering priced at $22.03 per share, materially strengthening Tyra’s funding position
- 9,079,000 shares plus pre-funded warrants for 9,078,529 shares, creating substantial potential dilution
Item 8.01: Other Events
- SURF302 supports selective FGFR3 inhibition, with 60 mg QD identified as the potential registrational adjuvant dose
- 60 mg cohort: 79% ORR and 64% best overall CR among 14 evaluable participants
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release attached as Exhibit 99.1, containing the substantive financial details
Item EX-99.1: Item EX-99.1
- September 2026 SURF302 readout: safety data from 40+ patients and efficacy data from 20+ patients across 50 mg and 60 mg cohorts
- BEACH301 fifth dose level adds 0.625 mg/kg; approximately 25-child safety-sentinel data expected end-Q1 2027
AI summaries of TYRA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for TYRA
Don't miss the next TYRA filing
- Alerts as it files. A push when TYRA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut TYRA, by share count.
- Ask anything. An AI agent that reads every TYRA filing and answers with sources.
TYRA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Buy | Sep 15, 2026 | 9,078,529 | $22.03 |
| Harris Todd | A | Sep 15, 2026 | 864 | $9.13 |
| Fuhrman Alan | A | Sep 15, 2026 | 951 | $9.13 |
| Rueb Yuliya | A | Sep 15, 2026 | 2,925 | $9.13 |
| Verjee Rehan | Buy | Sep 9, 2026 | 971.894 | $20.58 |
| Rothenberg Stephen Michael | A | May 28, 2026 | 13,160 | - |
| MORE ROBERT J | A | May 28, 2026 | 13,160 | - |
| Gulfo Adele M. | A | May 28, 2026 | 13,160 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Operating Income | -$79.9M | -$104.2M | -$132.8M |
| Net Income | -$69.1M | -$86.5M | -$119.9M |
| Balance Sheet | |||
| Total Assets | $225.9M | $363.6M | $282.6M |
| Equity | - | $343.2M | $259.2M |
| ROE | - | -25.2% | -46.3% |
| Per Share | |||
| EPS | $-1.62 | $-1.51 | $-2.01 |
| Cash Flow | |||
| Operating CF | -$50.1M | -$69.8M | -$95.1M |
| CapEx | $770K | $664K | $141K |
Source: XBRL data in Tyra Biosciences, Inc. (TYRA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate TYRA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 26 | $708.4M |
| Q1 2026 | 26 | $603.8M |
| Q4 2025 | 22 | $153.9M |
| Q3 2025 | 23 | $80.9M |
| Q2 2025 | 23 | $58.1M |
| Q1 2025 | 18 | $44.3M |
| Q4 2024 | 15 | $77.4M |
| Q3 2024 | 11 | $18.8M |
- T. Rowe Price Group+1.80M (+182%)
- FMR LLC (Fidelity)+1.17M (+15%)
- State Street Corp+924.3K (+76%)
- BlackRock+814.0K (+37%)
- Vanguard Capital Management LLC+382.5K (+34%)
- Ameriprise Financial−128.0K (-88%)
- Goldman Sachs Group−86.9K (-16%)
- Invesco Ltd−84.2K (-77%)
- Raymond James Financial−66.2K (-27%)
- Millennium Management−43.9K (-20%)
- D.E. Shaw & Co+20.2K
- U.S. Bancorp−11
Source: 13F-HR filings on SEC EDGAR (aggregated from 164 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
TYRA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Sep 21, 2026 | - | - | |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Sep 17, 2026 | - | - | - |
| SC 13G | Sep 17, 2026 | - | - | |
| 8-K | Sep 15, 2026 | - | Analysis | - |
| 4 | Sep 11, 2026 | - | - | - |
| 8-K | Sep 9, 2026 | - | Analysis | - |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| SC 13G | Jul 30, 2026 | - | - | |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 4 | Jun 1, 2026 | - | - | |
| 8-K | May 13, 2026 | - | Analysis | |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - | |
| 4 | May 7, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
TYRA SEC filings: frequently asked questions
Are TYRA insiders buying or selling?
In the last 90 days, Tyra Biosciences, Inc. (TYRA) officers, directors and 10% owners reported 1 open-market purchase worth $20,000 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold TYRA stock?
As of June 30, 2026, the largest Tyra Biosciences, Inc. (TYRA) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($284.9 million), BlackRock ($96.8 million), T. Rowe Price Group ($88.9 million), State Street Corp ($68.4 million), Vanguard Capital Management LLC ($48.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did TYRA report in its latest 8-K?
Tyra Biosciences, Inc. (TYRA) filed an 8-K on September 15, 2026 reporting Item 8.01 (Other Events). $400.0M gross proceeds from 9,079,000 shares and 9,078,529 pre-funded warrants.
What are the latest TYRA SEC filings?
Tyra Biosciences, Inc. (TYRA) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on September 15, 2026 and a Form 4 insider filing on September 17, 2026.
What is TYRA's SEC CIK number?
Tyra Biosciences, Inc. (TYRA)'s SEC Central Index Key (CIK) is 1863127. EDGAR lists every TYRA filing under that number.
Ask anything about TYRA
The research agent reads TYRA's filings, financials, insider trades and 13F holders, then answers with sources.